Adverse Effects of Memantine
Memantine is generally well-tolerated with the most common adverse effects being dizziness, headache, confusion, and constipation (occurring in ≥5% of patients), though these occur at rates similar to or only slightly higher than placebo. 1
Common Adverse Effects from Clinical Trials
Based on FDA labeling and controlled trials involving 1,862 dementia patients, the following adverse reactions occurred in ≥2% of patients at rates higher than placebo 1:
Most frequent (≥5%):
- Dizziness
- Headache
- Confusion
- Constipation
Other common reactions (2-5%):
- Agitation (notably, memantine often showed a protective effect against agitation in most studies) 2
- Nausea
- Diarrhea
- Falls
- Accidental injury
- Influenza-like symptoms
The overall discontinuation rate due to adverse events was essentially identical to placebo (10.1% vs 11.5%), with no individual adverse reaction causing discontinuation in ≥1% of patients at rates exceeding placebo 1. This favorable profile was consistent across both short-term (24-28 weeks) and long-term treatment (up to 2 years) 3.
Serious but Rare Adverse Effects
Postmarketing surveillance has identified serious adverse reactions that warrant awareness, though their frequency cannot be reliably estimated 1:
Hematologic: Agranulocytosis, leukopenia, neutropenia, pancytopenia, thrombocytopenia, thrombotic thrombocytopenic purpura
Cardiac: Congestive heart failure
Gastrointestinal: Pancreatitis
Hepatic: Hepatitis
Psychiatric: Suicidal ideation, manic episodes (case reports exist) 4
Renal: Acute renal failure, increased creatinine, renal insufficiency
Dermatologic: Stevens-Johnson syndrome
Neurologic: Seizures occurred in 0.2% of memantine-treated patients vs 0.5% on placebo in clinical trials 1
Important Clinical Considerations
Overdose presentations can include hypertensive urgency and unusual neuropsychiatric symptoms like echolalia (repetitive speech), which may be mistaken for disease progression rather than medication toxicity 5. Always conduct thorough medication reconciliation with caregivers.
Disease-specific cautions: One case report documented worsening of motor and cognitive symptoms in a patient with Lewy body dementia who was initially misdiagnosed with Alzheimer's disease; symptoms resolved after memantine discontinuation 6. Exercise caution in patients with uncertain dementia subtype.
Drug interactions: Conditions that alkalinize urine (pH >8) can reduce memantine clearance by ~80%, potentially increasing adverse effects. This includes carbonic anhydrase inhibitors, sodium bicarbonate, renal tubular acidosis, and severe urinary tract infections 1.
Renal impairment: Reduce target dose to 5 mg twice daily in severe renal impairment (CrCl 5-29 mL/min) 1.
The evidence consistently demonstrates that memantine's adverse effect profile is mild and comparable to placebo across multiple large-scale trials 2, 3, 7, making it one of the better-tolerated dementia medications available.